Phase I Study of Simmitecan Hydrochloride for Injection in Patients With Advanced Solid Tumor Tolerability and Pharmacokinetics
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Simmitecan (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors ShangHai HaiHe Pharmaceutical
- 18 Dec 2016 Status changed from active, no longer recruiting to completed.
- 21 Oct 2016 Planned End Date changed from 1 Sep 2016 to 1 Jan 2017.
- 18 Mar 2016 Planned End Date changed from 1 Jun 2014 to 1 Sep 2016 as reported by ClinicalTrials.gov.